文献速递遗传性与小管间质肾病

阿加糖酶α/β长期剂量依赖性对法布雷病肾脏组织学的影响

Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-06-16

本研究对20例经典型法布雷病患者的系列肾活检进行分析,评估阿加糖酶替代治疗最长14年的剂量依赖性效应。结果显示足细胞球三糖神经酰胺(Gb3)减少与累积剂量相关,但动脉/小动脉Gb3清除有限,提示当前治疗对血管的长期效果值得关注。

要点

  • 足细胞Gb3减少与阿加糖酶累积剂量相关(r=0.69,P=0.001)
  • 高剂量组动脉/小动脉内膜Gb3清除更明显(P=0.03)
  • 两组GFR和尿白蛋白无统计学差异,中膜Gb3未见显著变化

核心结论

  • 长期阿加糖酶治疗可减少经典型法布雷病患者足细胞Gb3,且与累积剂量相关。
  • 动脉/小动脉Gb3清除有限,提示当前治疗对血管的长期效果存在顾虑。
  • 男性残余血浆Lyso-Gb3与累积剂量相关(r=0.71,P=0.01)。

研究设计与样本

  • 20例经典型法布雷病患者(12例男性),起始酶替代治疗中位年龄21岁(范围7–62岁)。
  • 阿加糖酶-α或-β治疗中位9.4年(范围5–14年),并进行系列肾活检。
  • 低固定剂量组全程接受0.2 mg/kg隔周一次,高剂量组接受0.2–1.0 mg/kg隔周一次。
  • 肾活检按国际法布雷肾病研究组建议评分,并结合临床评估与生物标志物。

主要发现

  • 两组基线与终末GFR及尿白蛋白均无统计学差异。
  • 低固定剂量组足细胞Gb3减少-1.39(SD=1.04),P=0.004;高剂量组减少-3.16(SD=2.39),P=0.002。
  • 足细胞Gb3减少与累积阿加糖酶剂量相关(r=0.69,P=0.001)。
  • 高剂量组动脉/小动脉内膜Gb3显著清除,基线有内膜Gb3的7例均清除,1例新增内膜Gb3包涵体(P=0.03)。
  • 低固定剂量组残余血浆Lyso-Gb3为20.1 nmol/L(SD=11.9),高于高剂量组的10.4 nmol/L(SD=8.4)。

关键数值与推荐

  • 低固定剂量定义为阿加糖酶0.2 mg/kg隔周一次,全程不变。
  • 高剂量组阿加糖酶剂量范围为0.2–1.0 mg/kg隔周一次。
  • 肾活检病理评分依据国际法布雷肾病研究组推荐。

临床怎么用

  • 对经典型法布雷病患者,长期阿加糖酶治疗应关注累积剂量与足细胞Gb3清除的关系。
  • 需警惕当前酶替代治疗对动脉/小动脉血管病变清除有限,长期血管风险仍需监测。

局限性

  • 样本量小(20例),部分分析基于亚组。
  • 剂量分组非随机,剂量调整源于疾病进展、疗效欠佳或阿加糖酶-β短缺。
  • 随访中高剂量组剂量范围较宽,组间比较需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Dose-dependent clearing of podocyte globotriaosylceramide has previously been shown in patients with classic Fabry disease treated with enzyme replacement. Our study evaluates the dose-dependent effects of agalsidase therapy in serial kidney biopsies of patients treated for up to 14 years. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Twenty patients with classic Fabry disease (12 men) started enzyme replacement therapy at a median age of 21 (range =7-62) years old. Agalsidase-α or -β was prescribed for a median of 9.4 (range =5-14) years. The lower fixed dose group received agalsidase 0.2 mg/kg every other week throughout the follow-up period. The higher dose group received a range of agalsidase doses (0.2-1.0 mg/kg every other week). Dose changes were made due to disease progression, suboptimal effect, or agalsidase-β shortage. Serial kidney biopsies were performed along with clinical assessment and biomarkers and scored according to recommendations from the International Study Group of Fabry Nephropathy. RESULTS: No statistical differences were found in baseline or final GFR or albuminuria. Kidney biopsies showed significant reduction of podocyte globotriaosylceramide in both the lower fixed dose group (-1.39 [SD=1.04]; P=0.004) and the higher dose group (-3.16 [SD=2.39]; P=0.002). Podocyte globotriaosylceramide (Gb3) reduction correlated with cumulative agalsidase dose (r=0.69; P=0.001). Arterial/arteriolar intima Gb3 cleared significantly in the higher dose group, all seven patients with baseline intimal Gb3 cleared the intima, one patient gained intimal Gb3 inclusions (P=0.03), and medial Gb3 did not change statistically in either group. Residual plasma globotriaosylsphingosine levels remained higher in the lower fixed dose group (20.1 nmol/L [SD=11.9]) compared with the higher dose group (10.4 nmol/L [SD=8.4]) and correlated with cumulative agalsidase dose in men (r=0.71; P=0.01). CONCLUSIONS: Reduction of podocyte globotriaosylceramide was found in patients with classic Fabry disease treated with long-term agalsidase on different dosing regimens, correlating with cumulative dose. Limited clearing of arterial/arteriolar globotriaosylceramide raises concerns regarding long-term vascular effects of current therapy. Residual plasma globotriaosylsphingosine correlated with cumulative dose in men.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Skrunes R, Tøndel C, Leh S, et al. Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease. Clin J Am Soc Nephrol. 2017. PMID: 28625968. doi:10.2215/CJN.01820217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。